Equities research analysts expect that Fluidigm Co. (NASDAQ:FLDM) will post sales of $30.02 million for the current quarter, according to Zacks. Three analysts have provided estimates for Fluidigm’s earnings. The highest sales estimate is $30.70 million and the lowest is $28.76 million. Fluidigm posted sales of $32.33 million during the same quarter last year, which suggests a negative year over year growth rate of 7.1%. The company is scheduled to report its next quarterly earnings results on Thursday, February 6th.

According to Zacks, analysts expect that Fluidigm will report full-year sales of $114.75 million for the current year, with estimates ranging from $113.56 million to $115.50 million. For the next year, analysts anticipate that the firm will report sales of $125.64 million, with estimates ranging from $120.92 million to $134.60 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Fluidigm.

Fluidigm (NASDAQ:FLDM) last released its earnings results on Tuesday, November 5th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. The company had revenue of $26.50 million during the quarter, compared to analyst estimates of $28.74 million. Fluidigm had a negative return on equity of 25.11% and a negative net margin of 57.10%. Fluidigm’s quarterly revenue was down 8.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.13) earnings per share.

FLDM has been the subject of several recent analyst reports. Janney Montgomery Scott lowered Fluidigm from a “buy” rating to a “neutral” rating in a report on Wednesday, November 6th. UBS Group raised Fluidigm from a “neutral” rating to a “buy” rating and reduced their target price for the company from $14.00 to $7.00 in a report on Friday, October 18th. BidaskClub raised Fluidigm from a “sell” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Zacks Investment Research lowered Fluidigm from a “hold” rating to a “sell” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $10.81.

In other Fluidigm news, insider Levin Easterly Partners Llc sold 11,545 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $5.55, for a total transaction of $64,074.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cadence Capital Management LLC grew its holdings in Fluidigm by 1.1% during the third quarter. Cadence Capital Management LLC now owns 268,164 shares of the medical research company’s stock valued at $1,242,000 after purchasing an additional 2,928 shares during the period. State Board of Administration of Florida Retirement System grew its holdings in Fluidigm by 12.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 30,828 shares of the medical research company’s stock valued at $380,000 after purchasing an additional 3,420 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Fluidigm during the second quarter valued at $68,000. Prudential Financial Inc. grew its holdings in Fluidigm by 55.6% during the second quarter. Prudential Financial Inc. now owns 15,950 shares of the medical research company’s stock valued at $197,000 after purchasing an additional 5,700 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Fluidigm by 21,055.2% during the third quarter. Tower Research Capital LLC TRC now owns 6,135 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 6,106 shares during the period. 90.99% of the stock is owned by institutional investors and hedge funds.

Shares of FLDM stock remained flat at $$2.52 during trading on Wednesday. The stock had a trading volume of 367,200 shares, compared to its average volume of 898,362. The company has a market cap of $175.30 million, a P/E ratio of -3.15 and a beta of 2.11. The company has a current ratio of 2.89, a quick ratio of 2.44 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average is $3.54 and its two-hundred day moving average is $7.65. Fluidigm has a 52 week low of $2.12 and a 52 week high of $14.90.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Recommended Story: Systematic Risk and Investors

Get a free copy of the Zacks research report on Fluidigm (FLDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.